Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Folinozit is a nutritional supplement developed by Nafas Zist Pharmed, specifically formulated for the management of polycystic ovary syndrome (PCOS), insulin resistance, type 2 diabetes, and associated infertility. It is a combination product typically composed of myo-inositol and folic acid. Myo-inositol acts as a precursor for inositol phosphoglycans, which serve as second messengers in insulin and follicle-stimulating hormone (FSH) signaling pathways. This mechanism helps to improve insulin sensitivity, reduce compensatory hyperinsulinemia, and restore normal ovulatory cycles in women with PCOS. Folic acid is included to support DNA synthesis and cellular division, which is critical for reproductive health and the prevention of neural tube defects during early pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Folinozit.